

Dyslipidemia in Primary Care:

Addressing Barriers to Optimal Lipid Management

EVALUATION FORM

Date

August 30, 2018

Location

abc hotel 1234 unk

The Canadian Heart Research Centre is committed to excellence in continuing education and your opinions are critical to us in this effort. To assist us in evaluating the effectiveness of this program and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form.

Physician:										
Type of Practice: Full-time	Demographics									
Type of Practice: Full-time	Physician: Yes	□ No □	Other P	lease specify						
After participating in this activity, I am now better able to: 1. Recognize the centrality of LDL-C and its cumulative exposure to increased risk of ASCVD events Strongly disagree Disagree Neutral Agree Strongly agree		☐ Full-time			☐ Group	☐ Office	☐ Hospital	☐ Other		
1. Recognize the centrality of LDL-C and its cumulative exposure to increased risk of ASCVD events Strongly disagree	LEARNING OBJECTIVES:									
Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 2. Evaluate the limitations of current lipid lowering agents and assess recommendations for lipid lowering agents beyond, or in addition to, statin therapy for high risk patients Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 3. Identify those patients who would benefit from additional therapy beyond statins to reduce CV risk Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 4. Explain the latest clinical data for PCSK9 inhibitors and use effective strategies to integrate the data into clinical care to reduce the risk for CV events Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 5. Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Speaker / Moderator Speaker 1, last2 was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Speaker / Moderator	After participating in this activity, I am now better able to:									
1 2 3 4 5 2. Evaluate the limitations of current lipid lowering agents and assess recommendations for lipid lowering agents beyond, or in addition to, statin therapy for high risk patients Strongly disagree	1. Recognize the centrality of LDL-C and its cumulative exposure to increased risk of ASCVD events									
2. Evaluate the limitations of current lipid lowering agents and assess recommendations for lipid lowering agents beyond, or in addition to, statin therapy for high risk patients Strongly disagree	Strongly disagree	Disagr	ee	Neutral		Agree		Strongly agree		
statin therapy for high risk patients Strongly disagree Disagree Neutral Agree Strongly agree	1	2			3		4	5		
3. Identify those patients who would benefit from additional therapy beyond statins to reduce CV risk Strongly disagree Disagree Neutral Agree Strongly agree										
3. Identify those patients who would benefit from additional therapy beyond statins to reduce CV risk Strongly disagree Disagree Neutral Agree Strongly agree	Strongly disagree	Disagr	ee	Ne	utral	,	Agree	Strongly agree		
Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 4. Explain the latest clinical data for PCSK9 inhibitors and use effective strategies to integrate the data into clinical care to reduce the risk for CV events Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 5. Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Speaker / Moderator	1	2		3		4		5		
4. Explain the latest clinical data for PCSK9 inhibitors and use effective strategies to integrate the data into clinical care to reduce the risk for CV events Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 5. Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Speaker / Moderator Speaker 1, last2 was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program? Yes No	Identify those patie	ents who would bene	efit from addition	onal therapy b	eyond statins to	o reduce CV ris	sk			
4. Explain the latest clinical data for PCSK9 inhibitors and use effective strategies to integrate the data into clinical care to reduce the risk for CV events Strongly disagree	Strongly disagree	Disagr	ae .	Ne	utral	,	Agree	Strongly agree		
the risk for CV events Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 5. Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Speaker / Moderator Speaker 1, last2 was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program?	1	2			3		4	5		
1 2 3 4 5 5. Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Speaker / Moderator Speaker 1, last2 was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program?										
5. Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics Strongly disagree Disagree Neutral Agree Strongly agree	Strongly disagree	Disagr	ee	Ne	utral	,	Agree	Strongly agree		
Speaker / Moderator Speaker 1, last2 was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program?	1	2			3		4	5		
Speaker / Moderator Speaker 1, last2 was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program? Yes	5. Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics									
Speaker / Moderator Speaker 1, last2 was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program? Yes	Strongly disagree	Disagr	9e	Ne	utral		Agree	Strongly agree		
Speaker1, last2 was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program? Yes					3		4	5		
was effective in presenting the material: Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program? Yes	Speaker / Moderator									
Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program? ☐ Yes ☐ No	Speaker1, last2									
Strongly disagree Disagree Neutral Agree Strongly agree 1 2 3 4 5 Did you perceive any degree of bias in any part of the program? ☐ Yes ☐ No	was effective in presenting the material:									
Did you perceive any degree of bias in any part of the program? ☐ Yes ☐ No	2 3 3 5 5 T	-		Neutral		Agree		Strongly agree		
		2		3				5		
If Yes, please describe:	Did you perceive any degree of bias in any part of the program? ☐ Yes ☐ No									
	If Yes, please describe:									

Speaker / Moderator

was effective in presenting th	e material:							
Strongly disagree	Disagree	Neutral	Agree	Strongly agree				
Did you name ive any dames	2 of bigs in any next of the nex	3	4 □ No	5				
Did you perceive any degree	of bias in any part of the pro	ogram? Lifes	□ No					
If Yes, please describe:								
This Program			indicate with CAnMI	EDS roles you felt educational activity.				
Content enhanced my k	nowledge							
Strongly disagree No	eutral Strongly agree		ly Medicine Expert					
1 2	3 4 5	☐ Colla	nunicator					
Addressed my most pre	ssing questions							
	eutral Strongly agree	☐ Mana	h Advocate					
1 2	3 4 5							
	s or quality in health care	□ Profe						
Strongly disagree No.	Strongly agree 3 4 5	☐ Scho	ıar					
Was scientifically rigoro	ous and evidence-based							
Strongly disagree No	eutral Strongly agree							
1 2	3 4 5							
Provided appropriate and effective opportunities for active learning (ie., case studies, discussion, Q &A, etc)								
Strongly disagree No	eutral Strongly agree							
1 2	3 4 5							
Provided an opportunity	for interaction with my pe	eers						
	eutral Strongly agree							
1 2	3 4 5							
Based on your participation in this program, please select all applicable statement(s):								
☐ I gained new strategies/skills/information that I can apply to my area of practice.								
☐ I plan to implement new strategies/skills/information into my practice.								
☐ I need more information before I can implement new strategies/skills/information into my practice behavior								
☐ This program will not change my practice, as my current practice is consistent with the information presented.								
☐ This program will not change my practice, as I do not agree with the information presented.								
What strategies/changes do you plan to implement into your practice?								
What barriers do you see to making a change in your practice?								
Future Topics of Interest / Additional Comment & Suggestions								
Thank you for your feedback!								